Peter Timmerman

Dr. Peter Timmerman


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2019 in ACS Combinatorial Science
Verified
Journal Article
Open access
DBDominik Bernhagen
Dominik Bernhagen
VJVanessa Jungbluth
Vanessa Jungbluth
NQNestor Gisbert Quilis
Nestor Gisbert Quilis
JDJakub Dostalek
Jakub Dostalek
PWPaul B. White
Paul B. White
Peter TimmermanPeter Timmerman
Peter Timmerman
We describe the identification of bicyclic RGD-peptides with high affinity and selectivity for integrin αvβ3 via high-throughput screening of partly randomized libraries. Peptide libraries (~700 different compounds) comprising the universal integrin-binding sequence Arg-Gly-Asp (RGD) in the first loop and a randomized sequence XXX (X being one of 18 canoni-cal L-amino acids) in the second loop, both enclosed by either an L- or D-Cys residue, were converted to bicyclic peptides via reaction with 1,3,5-tris(bromomethyl)benzene (T3). Screening of 1st generation libraries yielded lead bicyclic inhibitors dis-playing submicromolar affinities for integrin αvβ3 (e.g. CT3HEQcT3RGDcT3, IC50: 195 nM). Next generation (2nd and 3rd) librar-ies were obtained by partially varying the structure of the strongest lead inhibitors and screening for improved affinities and selectivities. In this way, we identified the highly selective bicyclic αvβ3-binders CT3HPQcT3RGDcT3 (IC50=30 nM), CT3HPQCT3RGDcT3 (IC50=31 nM), and CT3HSQCT3RGDcT3 (IC50=42 nM) with affinities comparable to that of a knottin-RGD-type peptide (32 amino acids, IC50=38 nM) and outstanding selectivities over integrins αvβ5 (IC50 >10,000 nM) and α5β1 (IC50 >10,000 nM). Affinity measurements using Surface Plasmon-enhanced Fluorescence Spectroscopy (SPFS) yielded Kd values of 0.4 and 0.6 nM for Cy5-labeled bicycle CT3HPQcT3RGDcT3 and RGD ‘knottin’ peptide, respectively. In vitro stain-ing of HT29 cells with Cy5-labeled bicycles using confocal microscopy revealed strong binding to integrins in their natural environment, which highlights the high potential of these peptides as markers of integrin-expression.

16 April 2014 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
RWRike Wallbrecher
Rike Wallbrecher
LDLuc Depré
Luc Depré
Wouter VerdurmenWouter Verdurmen
Wouter Verdurmen
PBPetra H. Bovée-Geurts
Petra H. Bovée-Geurts
RDRichard H. van Duinkerken
Richard H. van Duinkerken
RBRoland Brock
Roland Brock

17 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MWMadelon Q. Wentink
Madelon Q. Wentink
THTilman M. Hackeng
Tilman M. Hackeng
STSebastien P. Tabruyn
Sebastien P. Tabruyn
WPWouter C. Puijk
Wouter C. Puijk
KSKlaus Schwamborn
Klaus Schwamborn
Peter TimmermanPeter Timmerman
Peter Timmerman
Significance: VEGF is the pivotal growth factor for angiogenesis, and its inhibition by passive immunotherapy results in improved survival in patients with several types of cancer. We believe that the clinical benefit could be increased by inducing a humoral immune response against VEGF through active immunization with VEGF-based peptides. In this study, we describe that correct peptide design is vital for success. We show that only 3D-structured peptides perfectly mimicking the crucial β5–turn–β6 loop of endogenous VEGF are able to induce neutralizing antibodies. We developed a vaccine with potent in vitro and in vivo VEGF-neutralizing activities, as shown in passive and active immunization tumor models. The VEGF vaccination strategy has the potential to outperform current clinical anti-VEGF treatment strategies.

1 December 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
Peter TimmermanPeter Timmerman
Peter Timmerman
RBRodrigo Barderas
Rodrigo Barderas
JDJohan Desmet
Johan Desmet
DADanièle Altschuh
Danièle Altschuh
SSSusana Shochat
Susana Shochat
RMRob H. Meloen
Rob H. Meloen
The great success of therapeutic monoclonal antibodies has fueled research toward mimicry of their binding sites and the development of new strategies for peptide-based mimetics production. Here, we describe a new combinatorial approach for the production of peptidomimetics using the complementarity-determining regions (CDRs) from gastrin17 (pyroEGPWLEEEEEAYGWMDF-NH(2)) antibodies as starting material for cyclic peptide synthesis in a microarray format. Gastrin17 is a trophic factor in gastrointestinal tumors, including pancreatic cancer, which makes it an interesting target for development of therapeutic antibodies. Screening of microarrays containing bicyclic peptidomimetics identified a high number of gastrin binders. A strong correlation was observed between gastrin binding and overall charge of the peptidomimetic. Most of the best gastrin binders proceeded from CDRs containing charged residues. In contrast, CDRs from high affinity antibodies containing mostly neutral residues failed to yield good binders. Our experiments revealed essential differences in the mode of antigen binding between CDR-derived peptidomimetics (K(d) values in micromolar range) and the parental monoclonal antibodies (K(d) values in nanomolar range). However, chemically derived peptidomimetics from gastrin binders were very effective in gastrin neutralization studies using cell-based assays, yielding a neutralizing activity in pancreatic tumoral cell lines comparable with that of gastrin-specific monoclonal antibodies. These data support the use of combinatorial CDR-peptide microarrays as a tool for the development of a new generation of chemically synthesized cyclic peptidomimetics with functional activity.


26 March 2019 in Organic Letters
Verified
Journal Article
Open access
DSDieuwertje E. Streefkerk
Dieuwertje E. Streefkerk
MSMarcel Schmidt
Marcel Schmidt
JIJohannes H. Ippel
Johannes H. Ippel
THTilman M. Hackeng
Tilman M. Hackeng
TNTimo Nuijens
Timo Nuijens
JMJan H. van Maarseveen
Jan H. van Maarseveen
In Nature, multicyclic peptides constitute a versatile molecule class with various biological functions. For their pharmaceutical exploitation, chemical methodologies that enable selective consecutive macrocyclizations are required. We disclose a combination of enzymatic macrocyclization, CLIPS alkylation, and oxime ligation to prepare tetracyclic peptides. Five new small molecular scaffolds and differently sized model peptides featuring noncanonical amino acids were synthesized. Enzymatic macrocyclization, followed by one-pot scaffold-assisted cyclizations, yielded 21 tetracyclic peptides in a facile and robust manner.